Equillium Inc

NASDAQ:EQ   3:59:40 PM EDT
+0.13 (+2.48%)
Products, Regulatory

Equillium Sees Filing U.S. IND For Itolizumab For COVID-19, Initiating Global Phase 3 Clinical Study In Q4

Published: 09/15/2020 12:51 GMT
Equillium Inc (EQ) - Equillium Announces Successful Completion of FDA Pre-ind Meeting Enabling Advancement of Itolizumab Into a Potential Registration Study As a Treatment for Hospitalized Covid-19 Patients.
Equillium Inc - Anticipates Filing a U.S. Ind for Itolizumab for Covid-19 and Initiating a Global Phase 3 Clinical Study in Q4.
Equillium Inc - Anticipates Beginning Formal Applications to Governmental Agencies for Funding Support of Clinical Study.
Equillium Inc - FDA Indicated Proposed Study, If It Meets Primary & Key Secondary Endpoints, May Be Sufficient for a Bla Submission.